An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients With Relapsed or Refractory (R/R) Select B-Cell Malignancies

Trial Profile

An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients With Relapsed or Refractory (R/R) Select B-Cell Malignancies

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs CLR 1404 I-131 (Primary) ; Dexamethasone
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Mantle-cell lymphoma; Multiple myeloma; Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Sponsors Cellectar Biosciences
  • Most Recent Events

    • 17 Jul 2017 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.
    • 17 Jul 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
    • 30 Mar 2017 Status changed from not yet recruiting to recruiting, according to a Cellectar Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top